NASDAQ: RPTXRepare Therapeutics Inc Stock
$3.15-0.15 (-4.55%)
Updated Apr 25, 2024
RPTX Price
$3.15
Fair Value Price
N/A
Market Cap
$132.87M
52 Week Low
$2.98
52 Week High
$13.85
P/E
-1.41x
P/B
0.63x
P/S
6.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$51.13M
Earnings
-$93.80M
Gross Margin
100%
Operating Margin
-201.79%
Profit Margin
-183.4%
Debt to Equity
0.2
Operating Cash Flow
-$127M
Beta
1.33
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
RPTX Overview
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RPTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RPTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RPTX is good value based on its book value relative to its share price (0.63x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
RPTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RPTX due diligence checks available for Premium users.
Be the first to know about important RPTX news, forecast changes, insider trades & much more!
RPTX News
Valuation
RPTX fair value
Fair Value of RPTX stock based on Discounted Cash Flow (DCF)
Price
$3.15
Fair Value
$0.00
Overvalued by
122,833.74%
RPTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RPTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.41x
Industry
15.41x
Market
40.97x
RPTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.63x
Industry
5.8x
RPTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RPTX's financial health
Profit margin
Revenue
$13.0M
Net Income
-$28.0M
Profit Margin
-214.8%
RPTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RPTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$253.9M
Liabilities
$41.8M
Debt to equity
0.2
RPTX's short-term assets ($243.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RPTX's short-term assets ($243.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RPTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RPTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.2M
Investing
$31.9M
Financing
$105.0k
RPTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RPTX vs Biotech Stocks
Repare Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.